Circulating tumor cells are focus of collaboration.

Immunicon entered into a research services agreement with Bristol-Myers Squibb involving protein and molecular targets associated with circulating tumor cells.

“Our collaborations span across protein biomarkers, phosphoproteins, and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs,” comments Leon Terstappen, M.D., Ph.D., CSO at Immunicon.

Previous articlePeregrine Pharmaceuticals Inks $50M mAb Development Deal with Dios Therapeutics
Next articleResearchers Find Biomarkers for Throat Cancer